The administrative core will provide essenfial support for all administrafive activities associated with the program project grant^or al| Project and Cores. The administrafive core will provide support for accounting, budgefing, fiscal reporting, protocol submission, dissemination of information between program sites, as well as preparafion and distribution of protocol revisions and yeariy renewal reporting. Protocol monitoring, data coordination, and communicafion among project and core key personnel through in-perSon meefings, regulariy scheduled conference calls, and additional telephone communication will be the responsibility of the administrafive core. Additionally, the core will support scheduling and coordination of internal research meefings and external consultant visits. The Core with centrally coordinate sample and clinical materials distribufion between Projects, participating clinical sites and Cores. The Core will also support clinical trials by coordinafion of research nurse support at the University site for the therapeijitic trials in Projects 2 and 3 and the prospective trials in Project 3.

Public Health Relevance

The administrafive and clinical support core will funcfion to make the group cohesive ahd integrated. This will be accomplished by promofing communication, external review ofthe program, central data collecfion and i safety monitoring and sample disseminafion.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
United States
Zip Code
Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2017) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant :
Robinson, James; Guethlein, Lisbeth A; Cereb, Nezih et al. (2017) Distinguishing functional polymorphism from random variation in the sequences of >10,000 HLA-A, -B and -C alleles. PLoS Genet 13:e1006862
Schmohl, Jörg U; Felices, Martin; Oh, Felix et al. (2017) Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity. Cancer Res Treat 49:1140-1152
Cichocki, Frank; Valamehr, Bahram; Bjordahl, Ryan et al. (2017) GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity. Cancer Res 77:5664-5675
Davis, Zachary B; Vallera, Daniel A; Miller, Jeffrey S et al. (2017) Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol 31:64-75
Hoff, Gretchen A; Fischer, Johannes C; Hsu, Katharine et al. (2017) Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes. Biol Blood Marrow Transplant 23:153-160
Boyiadzis, Michael; Bishop, Michael R; Abonour, Rafat et al. (2016) The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer 4:90
Bachanova, Veronika; Weisdorf, Daniel J; Wang, Tao et al. (2016) Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation. Biol Blood Marrow Transplant 22:1602-1607
Weisdorf, Daniel (2016) The role of second transplants for leukemia. Best Pract Res Clin Haematol 29:359-364
He, F; Warlick, E; Miller, J S et al. (2016) Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD. Bone Marrow Transplant 51:1107-12

Showing the most recent 10 out of 89 publications